MBLX, Metabolix, Inc.
** For the first quarter 2012, MBLX posted total revenue of $39.3 million, compared to $0.3 million in the same period the prior year, and net income of $28.8 million or $0.84 per share, compared to a net loss of $9.6 million or $0.36 per share for the first quarter of 2011.
The first quarter 2012 revenue consisted primarily of $38.9 million in deferred revenue which was recognized as a result of the termination of the Telles joint venture.
MBLX recently opened a European office in Cologne, Germany. This site will enable MBLX to directly access the European market for biopolymers and will serve as a coordination point for its regional initiatives in renewable chemicals. In addition, MBLX has entered into arrangements to warehouse PHA biopolymer product inventory in Europe and the United States, and has positioned inventory to serve these markets.
MBLX is an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals and energy industries. MBLX is developing and commercializing Mirel(TM) and Mvera(TM), a family of high-performance bioplastics which are biobased and biodegradable alternatives to many petroleum-based plastics.
More about MLBX at www.metabolix.com.
LMNX, Luminex Corporation
** LMNX reported that it has received CE marking of both the xMAP NeoPlex4 Assay and NeoPlex(R) System.
This unique system revolutionizes the way newborn screening is performed, providing four assays from one blood spot punch, reducing sample requirements and improving laboratory efficiency.
Millions of infants have blood drawn from their heel after birth to detect rare disorders that could threaten their life and long-term health. For most of these disorders, there is no medical history of the condition in the family and no way to predict the health of a baby based on the health of the parents. Early screening, diagnosis and proper treatment can decrease newborn morbidity, mortality and improve the infant's quality of life and life expectancy.
LMNX develops, manufactures and markets innovative biological testing technologies with applications throughout the clinical diagnostic and life science industries
More about LMNX at www.luminexcorp.com.
MRCY, Mercury Computer Systems, Inc.
** MRCY reported that it was selected by Raytheon Space and Airborne Systems (SAS) to provide an Application-Ready Subsystem(TM) (ARS(TM)) and integration services for Raytheon's Advanced Distributed Aperture System (ADAS).
MRCY will deliver an advanced sensor processing subsystem as part of Raytheon's Multi-function Image Processor (MIP), and systems integration services to help Raytheon realize unprecedented operational capabilities, allowing aircrews to achieve objectives with the lowest possible risk.
MRCY is providing a unique, high-performance sensor processing subsystem that leverages best-in-class heterogeneous processing elements including FPGAs, GPGPUs, and GPPs, interconnected with various high-speed switch fabrics. Highly ruggedized for harsh and mobile helicopter environments, the system will help improve mission effectiveness and flight safety at low altitude, in poor visibility and in hostile environments.
Aligning with procurement reform and industry best practices, the standards-based OpenVPX(TM) system is designed to allow for rapid future technology insertions either in terms of processing capabilities or handling new sensors or new modalities. The technology integration will be completed by MRCY's Services and Systems Integration team.
MRCY is a best-of-breed provider of open, commercially developed, application-ready, multi-INT subsystems for defense prime contractors.
More about MRCY at www.mc.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.